For this reason, the major emerging therapies seem to be aimed at the manipulation of the hepcidin–FPN axis, using hepcidin agonists or FPN inhibitors for iron overload disorders characterized by inappropriate/low hepcidin and hepcidin antagonists to favor iron release; as, for example, in anemia of inflammation. Here, HAMP is linked to anemia.